Is Novavax stock over? The company gave a terrible second-quarter report

Is Novavax stock over? The company gave a terrible second-quarter report
Photo by Maxim Hopman / Unsplash

Novavax, the manufacturer of vaccines against COVID-19, published a "killer" report. Revenue not only fell by 38% year-on-year, but was more than five times below analysts' expectations. The company cut its revenue forecast for 2022 from $4-4.5 billion to $2-2.3 billion.

There are several reasons for the terrible results. First, the company is not coping with competition from Moderna and Pfizer. Second, the cost of sales has risen because of overdue inventory. Third, demand for vaccines has declined because of a waning epidemic.

All of this led to a net loss of $510 million in the second quarter, versus $352 million a year earlier. Minutes before the report, trading in NVAX stock was suspended. The company was not saved by the approval of a protein vaccine against COVID-19.

Bottom line: Weakening COVID and strong competitor performance is a critical negative for the stock.